Idorsia's Oral Drug Shows Long-Term Kidney Hope in Fabry Disease

ALLSCHWIL, Switzerland – January 30, 2026

Idorsia Pharmaceuticals is set to unveil highly anticipated long-term data for its investigational oral drug, lucerastat, which suggests a significant potential to protect vital organs in patients with Fabry disease. The new findings, which include results from up to 42 months of continuous treatment and a detailed kidney biopsy analysis, will be presented next week at the 22nd Annual WORLDSymposium™, a premier scientific conference on lysosomal diseases.

The data reinforce the promise of lucerastat as a potential first-in-class oral substrate reduction therapy (SRT) for Fabry disease, a rare and progressive genetic disorder that causes debilitating damage to the kidneys, heart, and nervous system. For a patient community often burdened by frequent intravenous treatments, the development of an effective oral medication represents a potential paradigm shift in managing the disease.

Beyond the Primary Endpoint: A New Path for Lucerastat

The journey of lucerastat has been one of scientific perseverance. The drug's pivotal Phase 3 MODIFY study, the largest randomized trial ever conducted in Fabry disease, initially delivered mixed results. While it did not meet its primary endpoint of reducing neuropathic pain over a six-month period, the study revealed a powerful underlying effect: lucerastat significantly reduced levels of globotriaosylceramide (Gb3), the harmful fatty substance that accumulates in the cells of Fabry patients.

This robust biomarker reduction prompted Idorsia to continue investigating the drug's long-term potential through an open-label extension (OLE) study. More than 100 patients from the original trial enrolled, with some now having received continuous lucerastat therapy for over six years. It is from this long-term cohort that the new, promising data on organ protection have emerged, highlighting a crucial lesson in modern drug development: for chronic, progressive diseases, short-term endpoints may not tell the whole story.

Idorsia's strategy to look beyond the initial setback and focus on long-term, clinically meaningful outcomes like organ function is now poised to pay dividends, providing a potential new path forward for a drug that once faced an uncertain future.

A Glimmer of Hope for Organ Protection

The most compelling findings to be presented at WORLDSymposium center on lucerastat's impact on the kidneys and heart, the two organs most vulnerable to irreversible damage in Fabry disease. An earlier interim analysis of the OLE had already hinted at a positive trend, but the 42-month data are expected to provide a much clearer picture of the drug's disease-modifying potential.

One of the key presentations will focus on the drug's effect on kidney function, as measured by the estimated glomerular filtration rate (eGFR), a critical indicator of renal health. The data are expected to show a marked attenuation in the rate of eGFR decline among patients treated with lucerastat, particularly in those who had impaired or rapidly deteriorating kidney function at the start of the study. Slowing the progression to end-stage renal disease is a primary goal of Fabry treatment, and these results suggest lucerastat could be a vital tool in achieving it.

Further bolstering these findings is a second presentation detailing the results of a kidney biopsy sub-study. In this analysis, tissue samples from male patients with classic Fabry disease who received at least two years of lucerastat monotherapy were examined. This provides direct, cellular-level evidence of the drug's impact on Gb3 accumulation within key kidney cells, moving beyond blood-based biomarkers to show what is happening inside the organ itself.

In addition to the renal benefits, previous analyses have indicated a stabilization of cardiac function, with no worsening of left ventricular mass—a measure of the heart's thickness—over time. The new long-term data will provide further insight into the durability of this cardiac effect.

Redefining Treatment for a Rare Disease

For the estimated 21,000-plus patients diagnosed with Fabry disease across major global markets, current treatment options have significant limitations. The standard of care has long been enzyme replacement therapy (ERT), which requires lifelong, bi-weekly intravenous infusions. While effective for many, the treatment burden is substantial.

“For patients tethered to bi-weekly infusions, the prospect of a daily pill that could not only manage the disease but potentially offer better organ protection is transformative,” noted a leading nephrologist familiar with the challenges of Fabry disease management. “It addresses not only the clinical need but also the profound impact the disease and its treatment have on a person's quality of life.”

Another option, oral chaperone therapy, is only effective for patients with specific genetic mutations. Lucerastat's proposed advantage lies in its mechanism. As a substrate reduction therapy, it works by inhibiting the production of Gb3, making it effective regardless of a patient's specific GLA mutation. This genotype-independent approach, combined with its oral administration, could make it a suitable option for a much broader segment of the Fabry population, including those who do not respond well to or cannot tolerate existing therapies.

Idorsia's Regulatory Gambit and the Road Ahead

Armed with this compelling body of long-term evidence, Idorsia is actively finalizing a new development plan and engaging with regulatory agencies, including the U.S. Food and Drug Administration (FDA), to define the optimal pathway to approval. Pursuing a drug that missed its primary endpoint is a calculated risk, but one that is increasingly recognized as valid in the rare disease space, where surrogate endpoints and long-term functional outcomes can provide a more accurate measure of a drug's true value.

The company's ability to fund this continued development is bolstered by the commercial success of its insomnia treatment, QUVIVIQ, which has put Idorsia on a path to overall profitability. This financial stability provides the runway needed to navigate the complex regulatory landscape for lucerastat.

The full data presented at WORLDSymposium will be scrutinized by clinicians, researchers, and investors alike. The outcomes of Idorsia's subsequent discussions with regulators will be a critical milestone, determining whether this story of scientific perseverance will culminate in a new, much-needed therapeutic option for the global Fabry disease community.